Source: Washington Business Journal
Posted: March 20, 2007 12:16 PM EDT
Summary:
Neuralstem hopes to begin its first human clinical trial on a stem-cell product sometime this year and has raised more than $5 million to help fund the trial. The Rockville-based biotechnology company, whose focus is treatments based on the transplantation of human neural stem cells, raised about $5.14 million in a private placement of more than 2 million units at $2.50 per unit to a group of institutional investors.
